The latest update is out from Cabaletta Bio (CABA).
Cabaletta Bio, Inc. has announced a significant milestone as the U.S. FDA awarded Orphan Drug Designation to their innovative CAR T cell therapy, CABA-201, aimed at treating systemic sclerosis. This designation could potentially enhance the therapy’s development and approval process, offering new hope for patients with this rare autoimmune disease. Investors may view this update as a positive step for Cabaletta Bio’s growth in the biotechnology market.
Learn more about CABA stock on TipRanks’ Stock Analysis page.
